Drug Database
CE

cetuximab (Lupitux / Cetuxa / ENZ124)

✓ Approved

Lupin Limited · EGFR · Monoclonal Antibodies

What is cetuximab?

cetuximab is a monoclonal antibodies developed by Lupin Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesLupitux, Cetuxa, ENZ124
CompanyLupin Limited
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetEGFR
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Mechanism of Action

Molecular Targets

cetuximab acts on 1 molecular target:

EGFRepidermal growth factor receptor (ERBB1, NNCIS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

cetuximab is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Head and neck cancer metastatic✓ Approved

Related Research Articles

PubMedCritical reviews in oncology/hematology2026-09-15

Biomarker-guided treatment selection in metastatic colorectal cancer: A critical review of established and emerging therapies.

Tojjari Alireza A, Pourbahrighesmat Shamimeh S, Alkhazna Shahd S, Saeed Anwaar A

Metastatic colorectal cancer (mCRC) is increasingly managed according to mismatch repair status and actionable molecular alterations. In this structured narrative review, we separately examine mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) and microsatellite-stable/mismatch repair-proficient (MSS/pMMR) disease and distinguish established treatments from investigational strategies. In dMMR/MSI-H mCRC, immune checkpoint inhibition is the established first-line standard, with pembrolizumab and nivolumab plus ipilimumab producing durable disease control. In MSS/pMMR mCRC, tumor molecular findings guide targeted therapy. For BRAF V600E-mutant disease, encorafenib plus cetuximab with fluoropyrimidine-based chemotherapy is a first-line standard. HER2-directed therapy with tucatinib plus trastuzumab or trastuzumab deruxtecan and combined KRAS G12C and EGFR inhibition are established after prior treatment but are not approved in the first-line setting. Across MMR subgroups, rare NTRK or RET fusions can confer eligibility for tumor-agnostic TRK or RET inhibition, although CRC-specific cohorts remain small. In previously treated non-MSI-H/dMMR mCRC, STELLAR-303 was the first phase 3 trial to demonstrate a significant overall survival benefit with an immune checkpoint inhibitor-containing regimen, zanzalintinib plus atezolizumab. Other investigational strategies include additional immunotherapy combinations, EGFR-MET bispecific antibody therapy with amivantamab, T-cell-engaging bispecific antibodies, therapeutic cancer vaccines, cellular therapies, and microbiome-directed approaches. For each therapeutic class, we summarize the supporting evidence, define its place in the treatment sequence, and identify the remaining evidence gaps.

PubMedInternational journal of molecular sciences2026-09-15

The Role of Monoclonal Antibody Targeted Therapy (Panitumumab) in the Treatment of Metastatic Colorectal Cancer-A Narrative Review of Current Evidence and Emerging Therapeutic Strategies.

Kwiatkowska Lidia L, Szczuko Małgorzata M

Metastatic colorectal cancer (mCRC) remains one of the leading causes of cancer deaths worldwide. Mutations of the RAS and BRAF genes and the location of the primary tumor determine the choice of systemic therapy. Panitumumab-a fully human anti-EGFR monoclonal antibody-is well-established in the treatment of patients with wild-type RAS and BRAF and left-sided tumor localization. The aim of this review is to summarize the role and potential of targeted therapies for colorectal cancer with monoclonal antibodies such as panitumumab or cetuximab, to provide current evidence on the position of panitumumab in the treatment of mCRC, and to discuss biomarkers and qualification strategies for targeted therapy, including the role of ctDNA in disease monitoring and rechallenge. The work is based on a narrative review of literature from the PubMed, Scopus, Web of Science and Google Scholar databases, including publications available until May 2026. The efficacy of panitumumab was confirmed in phase III studies: first-line (PRIME: prolongation of OS by 5.6 months) and second-line treatment. A key condition for eligibility is complete RAS and BRAF genotyping, assessment of MSI/dMMR status, HER2 amplification, and tumor location. ctDNA analysis enables monitoring of tumor clonal evolution and qualification for rechallenge-the CHRONOS study showed 30% objective responses with liquid biopsy-based selection. Associations with BRAF/MEK and KRAS G12C inhibitors and modulation of the immune microenvironment via the CCL5/CCR5 axis remain promising directions. Panitumumab occupies an important position in the treatment of patients with mCRC, but increasingly precise molecular stratification and dynamic monitoring of disease with ctDNA are becoming the basis for the effective and rational use of the drug. Unlike reviews that selectively focus on individual aspects of anti-EGFR therapy, the following work integrates all aspects: from molecular biology and biomarkers used to qualify patients to clinical data on panitumumab and new strategies in the fight against mCRC. Further development of next-generation sequencing methods and standardization of ctDNA panels will be crucial for the widespread deployment of targeted therapies in everyday clinical practice. The role of panitumumab is well established in appropriately selected patients with RAS wild-type, particularly left-sided, metastatic colorectal cancer (mCRC). Combining panitumumab with immune checkpoint inhibitors warrants further investigation, particularly in patients with MSS/pMMR mCRC. The observed activity of panitumumab in combination with nivolumab and ipilimumab provides a rationale for further clinical evaluation and monitoring.

PubMedBiochemistry and biophysics reports2026-09-13

Quantitative dot blot method for measuring EGFR protein levels in patients with colorectal cancer.

Li Ze Z, Li Na N, Li Quanyong Q, Xu Wenlei W et al.

The expression levels of the epidermal growth factor receptor (EGFR) may be associated with the efficacy of cetuximab (CTX); however, conventional immunohistochemical assays lack quantitative accuracy and standardization, thereby making it hard to achieve absolute quantification of protein expression and cross-platform comparisons. To establish an objective quantitative standard for EGFR protein expression levels, we employed quantitative dot blotting (QDB) to analyze tumor samples from patients with RAS/BRAF wild-type colorectal cancer (CRC). We collected 89 formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens from patients with CRC stored at Yuhuangding Hospital in Yantai for QDB testing. Of these, 42 served as untreated controls, and 47 patients received CTX treatment. EGFR protein levels in all patients with CRC ranged from 0.05 to 3.85 nmol/g (n = 89). Using the predefined cohort-wide cutoff of 0.23 nmol/g, a chi-square test performed using the Statistical Package for the Social Sciences software revealed that patients with low EGFR expression had longer overall survival, regardless of CTX treatment. This study established a QDB-based assay capable of quantitatively and objectively measuring EGFR protein levels in CRC specimens. This assay helps establish the value of EGFR protein as a predictive biomarker and is expected to assist in the retrospective and prospective evaluation of anti-EGFR therapies in clinical trials.

PubMedBMJ open2026-09-13

FOLFOX-based transarterial infusion chemotherapy for unresectable colorectal cancer: protocol of an open-label, multicentre, randomised, controlled, phase II trial.

Wang Junpeng J, Sun Yan Y, Chen Longchang L, Wang Zheng Z et al.

Colorectal cancer (CRC) is the third leading cause of new cancer cases and the second leading cause of cancer-related deaths worldwide. Current therapeutic modalities for CRC include surgical resection, intravenous chemotherapy (IVC), radiotherapy, immunotherapy, targeted therapy and their combinations. As a mainstream systemic treatment for CRC, IVC leads to widespread drug distribution but relatively low intratumoural drug accumulation. Compared with IVC, transarterial infusion chemotherapy (TAIC) involves selective arterial catheterisation to deliver chemotherapeutic agents directly to the tumour feeding vessels. Hepatic tumours receive their blood supply predominantly through branches of the hepatic artery. Hepatic artery infusion chemotherapy (HAIC) yields significantly superior outcomes compared with IVC and is currently widely employed for the treatment of primary and secondary hepatic malignancies. HAIC in combination with IVC can offer long-term durable disease control in the clinical treatment of liver cancer compared with IVC. CRC is also predominantly grown through angiogenesis. Therefore, we raise the question whether sequential IVC administered after intensive TAIC achieves better clinical efficacy than IVC alone for the treatment of unresectable CRC (uCRC). However, no prospective clinical trials have been conducted to compare the efficacy of these two strategies. This prospective study was therefore designed to fill this clinical knowledge gap. This is a prospective, multicentre, randomised, open-label clinical trial. The uCRC is defined as inability to achieve an R0 resection owing to locally advanced CRC with clinical T4 disease confirmed by MRI or CT and/or synchronous liver metastases. This study only includes microsatellite stable or proficient mismatch repair uCRC. A total of 50 eligible patients will be randomly assigned to either the IVC group or the TAIC group. Patients in the IVC group will receive FOLFOX (fluorouracil, leucovorin, oxaliplatin)-based IVC every 2 weeks for a total duration of 8 weeks. Patients in the TAIC group will receive FOLFOX-based TAIC at week 0 and week 4 and receive FOLFOX-based IVC at week 2 and week 6. For patients with colorectal liver metastases, cetuximab or bevacizumab will be administered according to the RAS and BRAF status and the primary tumour site. The primary endpoint is the objective response rate. This study is scheduled to commence on 10 January 2026, and complete follow-up on 31 December 2027. The first subject was enrolled on 20 March 2026. To date, one subject in the IVC group and six subjects in the TAIC group have been enrolled. The present study protocol has been approved by the Medical Ethics Committee of Guang'anmen Hospital, China Academy of Chinese Medical Sciences (ethical approval number 2025-268 KY). On completion of the study, data cleaning and analysis will be performed, and the results will be disseminated at academic conferences and in international peer-reviewed journals. This trial has been registered at ClinicalTrials.gov. The statistical analysis plan will be finalised and approved before the database lock. The final version is retained in the study documentation and will be made available to support the transparency and interpretation of the study results. NCT07333053.

PubMedClinical and translational medicine2026-09-11

Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild-type metastatic colorectal cancer: A nonrandomised clinical trial.

Wang De-Shen DS, Chen Wen-Chuan WC, Ren Chao C, Wang Feng-Hua FH et al.

Mutant subclones driving anti-EGFR resistance may progressively decline after therapy cessation, potentially reversing resistance to EGFR-targeted treatment. We therefore examined whether rechallenge with cetuximab plus irinotecan is active and tolerable in patients selected by circulating tumour DNA (ctDNA) testing, focusing on metastatic colorectal cancer (mCRC) with RAS/BRAF wild-type (WT) status. This single-arm, Phase II clinical trial enrolled patients between November 2019 and February 2025. Eligible patients had histologically confirmed RAS/BRAF WT mCRC at diagnosis, prior cetuximab-based first-line therapy with clinical benefit, radiographic progression while on cetuximab or within 3 months after stopping it, subsequent progression after at least 1 additional systemic therapy, a cetuximab washout period of at least 4 months, and ctDNA-confirmed RAS/BRAF WT status before rechallenge. Each 2-week cycle delivered intravenous cetuximab (500 mg/m2) together with irinotecan (180 mg/m2). The primary endpoint was the objective response rate (ORR). We additionally assessed progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). This study enrolled 36 patients. Partial response was seen in 6 patients (16.7%), stable disease in 10 (27.8%), and progressive disease in 16 (44.4%); the remaining 4 patients were unevaluable due to early loss to follow-up. The ORR reached 16.7% (95% CI: 7.9-31.9), with a disease control rate of 44.4% (95% CI: 29.5-60.4). The median PFS and OS were 3.9 months (95% CI: 3.1-4.7) and 13.0 months (95% CI: 8.1-17.9). Multivariate Cox regression analyses identified screening time interval (STI) as an independent predictor of PFS (HR = 0.93 per additional month; 95% CI: 0.88-0.99). TRAEs of grade 3-4 were uncommon and clinically manageable. These findings suggest that ctDNA-guided rechallenge with cetuximab plus irinotecan may offer benefit in RAS/BRAF WT mCRC, with STI potentially informing patient selection. Nevertheless, further validation in larger randomised trials is warranted. ClinicalTrials.gov Identifier: NCT04224415. RAS/BRAF wild-type status confirmed by ctDNA may identify candidates for cetuximab rechallenge. A longer screening time interval was associated with improved progression-free survival. These hypothesis-generating findings warrant validation in larger randomised trials.

PubMedGan to kagaku ryoho. Cancer & chemotherapy2026-09-11

[Three Cases of Encorafenib Treatment for Recurrent BRAF-Mutated Colorectal Cancer].

Ozasa Haruka H, Nanishi Kenji K, Arita Tomohiro T, Shimizu Hiroki H et al.

Recently, favorable outcomes from encorafenib treatment have been reported in patients with BRAF-mutated colorectal cancer, which has a poor prognosis. Encorafenib was administered to three patients with recurrence after surgery for BRAF-mutated colorectal cancer. Encorafenib and cetuximab were administered to 2 patients, and encorafenib, binimetinib, and cetuximab were administered to one patient. In all cases, tumor markers decreased, and the metastatic tumors shrank. No severe adverse effects were observed. BRAF-mutated colorectal cancer often occurs in the right colon. It is also common in older patients, women, and patients with poorly differentiated tumors; our cases exhibited similar characteristics. As previously reported, both doublet and triplet encorafenib treatments are safe and effective. Combination therapy with encorafenib was effective for the treatment of recurrent BRAF-mutated colorectal cancer, showing good tumor control with few adverse effects. Therefore, this may be a useful treatment option.

+8720 more articles available with a free account

Sign up free to view all articles →

Ask about cetuximab